The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Eisai; EMD Serono; Galera Therapeutics; Genmab; GlaxoSmithKline; Merck; Merus; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Laurent Mortier
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Sun pharma
Consulting or Advisory Role - BMS GmbH & Co. KG; Novartis; Sun Pharma
Research Funding - MSD Oncology (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech; Roche/Genentech
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Ravindra Uppaluri
Consulting or Advisory Role - Daichi-Sankyo; Merck; Regeneron
Research Funding - Daichi-Sankyo; Merck
Patents, Royalties, Other Intellectual Property - Washington University licenses mouse oral cancer cell lines made by my lab. I receive royalties from Washington University from these agreements.
 
Inge Marie Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer
 
Philippe Saiag
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; pierre fabre; Roche
 
Annette May Ling Lim
(OPTIONAL) Uncompensated Relationships - Sanofi/Regeneron (Inst)
 
Ainara Soria Rivas
Consulting or Advisory Role - Bristol-Myers Squibb; IMMUNOCORE; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre
 
Richard A Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Cecilie Abildgaard
Employment - IO Biotech
Consulting or Advisory Role - AnRes Clinical
 
Qasim Ahmad
Employment - IO Biotech
Stock and Other Ownership Interests - IO Biotech
Travel, Accommodations, Expenses - IO Biotech
 
Francois Philippe Ringeisen
Employment - IO Biotech
Stock and Other Ownership Interests - IO Biotech
 
Diane Opatt McDowell
Employment - Bristol-Myers Squibb; IO Biotech
Leadership - IO Biotech
Stock and Other Ownership Interests - Bristol-Myers Squibb; IO Biotech
 
Barbara Burtness
Consulting or Advisory Role - Abbvie; ALX Oncology; Arvinas; Coherus Biosciences; CUE Biopharma; Eisai; Genentech/Roche; IO Biotech; Janssen Oncology; Kura Oncology; Macrogenics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Orphagen Pharmaceuticals; Rakuten Medical; Seagen; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); IO Biotech (Inst); Merck; Merck (Inst)
Expert Testimony - Cel-Sci Corporation